The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...
Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
Both Cas9 and Cas12a cleave DNA, but they differ in how they cut the molecule.
Hossain and coworkers investigate the mechanisms of recognition of xCas9, a variant of Cas9 with expanded targeting capability ... why xCas9 exhibits improved recognition of the TGG PAM sequence ...
The emergent field of CRISPR/Cas sensing technology is showing promise as a new paradigm in clinical diagnostics, although widespread clinical adoption remains limited. This perspective paper ...
In the realm of genome editing, LNPs have emerged as a potent vehicle for delivering CRISPR/Cas components, offering significant advantages such as high in vivo efficacy. The incorporation of machine ...
The discovery of clustered regularly interspaced short palindromic repeats (CRISPR) DNA segments and CRISPR-associated proteins (Cas), known as CRISPR/Cas, has revolutionized biomedical research ...
Kennedy Jr. will di­vest his in­ter­ests in sev­er­al bio­phar­ma com­pa­nies, in­clud­ing CRISPR Ther­a­peu­tics and Drag­on­fly Ther­a­peu­tics, if con­firmed by the ...
One of the people who served jail time for taking part in the US Capitol riot four years ago has refused a pardon from President Donald Trump, saying: "We were wrong that day." Pamela Hemphill ...